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Abstract 
Importance: The prognostic role of the extent of lymphadenectomy during surgery for 
esophageal cancer is uncertain and requires clarification.  
Objective: We aimed to clarify whether the number of removed lymph nodes influences 
mortality following surgery for esophageal cancer.  
Design: This was a cohort study of patients who underwent esophagectomy for cancer in 
2000-2012 at St Thomas’ Hospital London, with follow-up until 2014.  
Setting: A high-volume hospital for esophageal cancer surgery, St Thomas’ Hospital in 
London, United Kingdom.  
Participants: Consecutive patients with esophageal cancer who underwent surgical 
resection at the hospital.  
Exposures: The main exposure was number of resected lymph nodes. Secondary exposures 
were number of metastatic lymph nodes and positive-to-negative lymph node ratio.  
Main outcome measure: The independent role of the extent of lymphadenectomy in 
relation to all-cause and disease-specific 5-year mortality was analyzed using Cox 
proportional hazard regression models, providing hazard ratios (HR) with 95% confidence 
intervals (CI). The HRs were adjusted for age, pathological T-stage, tumor differentiation, 
margin status, calendar period of surgery, and response to pre-operative chemotherapy.  
Results: Among 606 included patients, the extent of lymphadenectomy did not statistically 
significantly influence all-cause or disease-specific mortality, independent of the 
categorization of lymphadenectomy or stratification for T-stage, calendar period, or 
chemotherapy. Patients in the 4th quartile of number of removed nodes (21-52 nodes) did 
not demonstrate statistically significantly reduction in all-cause 5-year mortality compared 
with those in the lowest quartile (0-10 nodes) (HR=0.86, 95% CI 0.63-1.17), particularly not in 
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the most recent calendar period (HR=0.98, 95% CI 0.57-1.66 years 2007-2012). A greater 
number of metastatic nodes and a higher positive-to-negative node ratio predicted strongly 
increased mortality rates, and these associations showed dose-response associations.  
Conclusions and Relevance: This cohort study indicates that the extent of lymphadenectomy 
during surgery for esophageal cancer might not influence the 5-year all-cause or disease-
specific survival. These results challenge current clinical guidelines.    
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Introduction 
Esophageal cancer is the 6th most common cause of cancer death globally,1 and the 
incidence of esophageal adenocarcinoma is increasing while the prognosis remains poor 
(<15% 5-year survival).2 Curatively intended treatment with surgery, typically preceded by 
oncological therapy,3 offers a limited (30%) chance of 5-year survival.4,5 The optimal extent 
of lymphadenectomy is controversial and requires clarification.5-9 Esophageal cancer spreads 
readily in a multidirectional fashion through the extensive submucosal lymphatics that drain 
the esophagus, and the presence of metastatic lymph nodes are the strongest known 
prognostic factors.5 This implies that more extensive lymphadenectomy should improve 
survival. On the other hand, it is still unclear whether the more extensive removal of regional 
(metastatic or not) nodes actually contributes to the cure of esophageal cancer patients. 
There is a possible trade-off between the potential survival benefit with more extensive 
lymphadenectomy and a decreased postoperative morbidity with less extensive 
lymphadenectomy.5-9 Although based on a limited number of studies with methodological 
concerns with stage migration and confounding, current clinical guidelines recommend 2-
field (extensive) lymphadenectomy.6,7,10 Yet, in routine clinical practice the limited scientific 
knowledge leaves it up to the discretion of the individual surgeon to decide the preferred 
extent of lymphadenectomy.8,9 The present study was prompted by the lack of survival 
benefit from a more extensive lymphadenectomy in our recent population-based Swedish 
cohort study.11 Here, we aimed to test whether the results of that previous study replicated 
using another design and based on another population. Here we used a prospective and 
comprehensive clinical data collection from a high-volume surgery center in London with 
surgeons and pathologist specialized in the field of esophageal cancer. 
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Methods 
Study design 
This cohort study included all surgically treated esophageal cancer patients at a high-volume 
center in London, United Kingdom (St Thomas’ Hospital) between 2000 and 2012, with 
follow-up until January 2014. An earlier version of this cohort has been used in previous 
publications.12,13 In brief, all operated patients with esophageal cancer were followed up 
until death or the end of the study period, whichever occurred first. The main study 
exposure was the number of removed lymph nodes. Secondary study exposures were the 
number of metastatic lymph nodes and the ratio of metastatic to total number of lymph 
nodes. The outcomes were all-cause and disease-specific 5-year mortality. The 5-year cut-off 
was used since deaths occurring later are usually not due to tumor recurrence.4  Ethical 
approval was granted for use of the database. 
 
Surgery 
The main surgical approaches were transhiatal or transthoracic (open or minimally invasive) 
esophagectomy. The preferred esophageal substitute was gastric conduit, anastomosed to 
the proximal esophagus in the thorax or neck. There were three consultant surgeons 
conducting the operations during the study period. There was no consensus about the 
preferred extent of lymphadenectomy.  
 
Histopathology  
All resected tumors underwent careful review by a consultant specializing in upper 
gastrointestinal histopathology. Tumor stage was classified according to the 7th edition of 
the American Joint Committee on Cancer TNM staging system.14 Pathologic tumor regression 
6 
 
following pre-operative chemotherapy was assessed according to the Mandard scoring 
system, ranging from 1 (complete response) to 5 (no response).15 In this study, the Mandard 
score was dichotomized, as planned a priori, into a “good” (scores of 1-3) or “poor” (scores 
of 4-5).  
 
Statistical analysis 
Cox proportional hazard modelling was used to analyze associations between the three 
lymphadenectomy exposure variables (total number of lymph nodes, number of positive 
lymph nodes and ratio of positive and total number of lymph nodes) and the two mortality 
outcomes (time to all-cause and disease-specific mortality with 5 years of follow-up). The 
categorization of total number of removed nodes into decentiles and quartiles was planned 
before any analyses were initiated. Since there were no dose-response associations between 
the total number of removed lymph nodes and mortality in the analysis using decentiles, we 
found it inappropriate to analyze the total number of lymph nodes as an ordinal variable. 
Thus, we only analyzed the total number of lymph nodes as a categorical variable. The 
current version of the N-coding system was used to categorize the number of positive lymph 
nodes (0, 1-2, 3-6, or >6).16 The ratio of positive and total number of lymph nodes was 
categorized into four groups (decided before analyses), where the 0 ratio was categorized 
into one group, and the rest of data split into tertiles. The first group (lowest lymph node 
harvest, no metastatic nodes and metastatic to non-metastatic ratio of 0) was used as the 
reference for all lymphadenectomy variables. Hazard ratios (HR) with 95% confidence 
intervals (CI) were derived from the model. HRs were presented as unadjusted  and adjusted 
for six pre-defined potential confounding factors: 1) age (continuous variable); 2) 
pathological T-stage (categorized a priori into 2 groups: T0-T2 or T3-T4); 3) tumor grade (3 
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groups: high-grade dysplasia and well-differentiated, moderately differentiated or poorly 
differentiated); 4) margin status (2 groups: R0 or R1/R2 [within 1 mm from the 
circumferential margin]); 5) response to pre-operative chemotherapy (3 groups: not 
applicable, good response [Mandard score 1–3], or poor response [Mandard score 4–5]); 6) 
calendar period (2 groups: years 2000-2006 or 2007-2012). Furthermore, we evaluated if the 
adjusted HRs for the lymphadenectomy variables were modified by T-stage (T0-T2 or T3-T4), 
calendar period (2000-2006 or 2007-2012) or response to chemotherapy (not applicable, 
good, or poor) using a product term in the regression models. The HRs and CIs were derived 
by the hazard ratio statement in the model. Furthermore, nine more variables were created 
with a combination of each lymphadenectomy exposure and T-stage (T0-T2 or T3-T4), 
calendar period (2000-2006 or 2007-2012), and response to chemotherapy (not applicable, 
good, or poor). These stratified analyses were conducted as a potential survival benefit with 
more extensive node removal might be higher in more advanced tumors,17 as treatment 
might change over calendar time and as chemotherapy and the response to it might 
influence any survival benefits of more extensive lymphadenectomy. To manage partial 
missing data for Mandard scores (5.3% of the patients had missing data) both complete case 
analysis and multiple imputation were conducted. The imputation variables were 
categorized as presented above and included age, pathological T-stage, tumor grade, margin 
status, response to pre-operative chemotherapy, and all-cause mortality. The number of 
imputed data sets was 20 and monotone logistic method in PROC MI was used under the 
assumption that the missing data were missing at random (MAR).18 PROC MIANALYZE was 
used to combine the results from the analyses of the 20 datasets. Since the results were 
similar between the two missing values approaches, we decided to present only HRs and CIs 
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from the multiple imputation. To avoid influence of collinearity of the exposure variables, 
these variables were analysed separately without adjusting for any of the other.  
To validate the results, we performed a sensitivity analysis by calculating propensity scores. 
Logistic regression with generalized logit function was used with total number of lymph 
nodes in quartiles and the six covariates in the model. The distribution of propensity score 
by outcome group was similar. The propensity scores divided into quintiles were then used 
in the Cox proportional hazard model as a covariate by each pair of the total number of 
lymph nodes comparison. The data management and statistical analyses were performed 
with SAS version 9.4 (SAS Institute, Inc., Cary, NC). 
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Results 
Patient characteristics 
The study included 606 patients, the majority with a diagnosis of adenocarcinoma of the 
esophagus (83.5%) while fewer patients had squamous cell carcinoma (15.2%) or adeno-
squamous carcinoma (1.3%) of the esophagus. Characteristics of these participants, in total 
and split into quartiles by the extent of lymphadenectomy, are presented in Table 1. Among 
323 (53%) patients who died within 5 years of surgery, 235 (39%) died from tumor 
recurrence. The age distribution was similar between patients in the four lymphadenectomy 
categories. More advanced T-stages were slightly overrepresented in the higher two 
quartiles of lymphadenectomy, while well-differentiated tumors and tumors with high-grade 
dysplasia or complete pathological response were overrepresented in the lower two 
quartiles of lymphadenectomy. A higher proportion of patients received preoperative 
chemotherapy during the last calendar period (77% in 2000-2006) compared to the first 
calendar period (53% in 2007-2012). The lymph node yield was higher during the later 
calendar period than the earlier period. The median number of removed nodes during the 
entire study period was 14 (range 0-52). The in-hospital postoperative mortality was 3% (18 
patients out of 606).   
 
Lymph node variables and 5-year mortality 
There was no dose-response association between lymphadenectomy levels and 5-year 
mortality when 10 or 4 categories of lymphadenectomy were assessed (Table 2). The crude 
HRs generally indicated a tendency of increased mortality, while the adjusted HRs generally 
indicated the opposite. It was mainly the adjustment for T-stage and tumor differentiation 
that decreased the HRs in the adjusted model (data not shown). However, none of the HRs 
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was statistically significant (Table 2). The adjusted HR for all-cause 5-year mortality in the 
highest quartile of lymphadenectomy (21-52 nodes) was 0.86 (95% CI 0.63-1.17) compared 
to the lowest quartile (0-10 nodes). There were strong dose-response associations between 
the number of metastatic nodes and mortality as well as the ratio of positive and total 
number of lymph nodes and mortality (Table 2). There were generally no major differences 
between all-cause and disease-specific 5-year mortality (Table 2).  
 
Lymph node variables and T-stage specific 5-year mortality 
No statistically significant associations were found in the analysis stratified for T-stages 
(Table 3). However, the HRs for all-cause 5-year mortality were slightly lower with more 
extensive lymphadenectomy in more advanced tumors (T3-T4) (HR 0.80, 95% CI 0.54-1.19 in 
the 4th quartile) compared to the less advanced tumors (T0-T2) (HR 0.96, 95% CI 0.58-1.60 in 
the 4th quartile). The prognostic influence of metastatic nodes and the ratio of positive and 
total number of lymph nodes were of similar strength in less and more advanced T-stages 
(Table 3). The HRs of disease-specific mortality did not differ much from those of the all-
cause mortality (Table 3). 
 
Lymph node variables and calendar period specific 5-year mortality 
In analyses stratified by the calendar periods 2000-2006 and 2007-2012, no statistically 
significant associations were found between total lymphadenectomy and all-cause or 
disease-specific 5-year mortality (Table 4). The point HRs of total lymphadenectomy during 
the earlier period were slightly decreased, while the HRs were close to 1 in the more recent 
calendar period (Table 4). The HR of all-cause mortality was 0.98 (95% CI 0.57-1.66) in the 
highest quartile of lymphadenectomy compared to the lowest during the more recent period 
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(2007-2012). The associations between the number of metastatic nodes and mortality, as 
well as the ratio of positive and total number of lymph nodes and mortality, were stronger 
during the later calendar period compared to the earlier, and the disease-specific HRs were 
higher compared to the all-cause HRs (Table 4). The highest quartiles of metastatic nodes 
(>6) and lymph node ratio (>0.37) had HRs of 6.00 (95 % CI 2.83-12.7) and 7.12 (95 % CI 3.47-
14.6), respectively, compared to the corresponding lowest quartiles (0 and 0).   
 
Lymph node variables and 5-year mortality following chemotherapy response 
The analyses stratified for pre-operative chemotherapy revealed no statistically significant 
associations between the extent of lymphadenectomy and mortality in any of the 
stratification categories (Table 5). The HRs of mortality were close to 1 in the non-
chemotherapy group (all-cause HR 1.03, 95% CI 0.56-1.90 and disease-specific HR 0.97, 95% 
CI 0.46-2.06, comparing the highest and lowest quartiles). The HRs of mortality tended to be 
slightly decreased in both good and poor responders to pre-operative chemotherapy (Table 
5). The number of metastatic nodes and the ratio of metastatic to all nodes were both 
strongly associated with risk of mortality in all three chemotherapy categories, but possibly 
even more so in the group of poor responders (Table 5).   
 
Lymph node variables and 5-year mortality using other reference categories 
The stratified results while using other reference categories are presented in a 
Supplementary Table. There was no influence of the total number of removed nodes on all-
cause or disease-specific mortality, while metastatic nodes and the ratio of metastatic and 
all nodes were strongly prognostic. An additional analysis of the risk of mortality in patients 
in quartiles of total lymphadenectomy in each of the four categories of metastatic nodes 
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revealed no patterns of any decreased mortality with more extensive lymphadenectomy 
(data not shown).  
 
The propensity score analysis resulted in similar risk estimates as in the Cox regression 
analysis, and therefore these results are not presented.     
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Discussion 
This study did not provide any support for the notion that the extent of lymphadenectomy 
during surgery is a prognostic factor in esophageal cancer. Although most point risk 
estimates were decreased, the HRs were generally close to zero effect, and were particularly 
so for earlier T-stages, during the more recent calendar period and in patients who did not 
have pre-operative chemotherapy. A higher number of metastatic nodes and a higher ratio 
of positive and total number of lymph nodes were, as expected, strong and dose-dependent 
prognostic factors.  
 
Some methodological issues merit attention before moving on to discuss the findings of the 
present study. The cohort design is the best available for studies specifically addressing in 
detail the effects of the number of removed lymph nodes. It is not feasible to randomize 
patients into numerous categories of lymphadenectomy, and thus an interventional study 
design is not an option for this purpose. An additional strength is the exclusive inclusion of 
patients operated on at a high-volume center, avoiding potential bias resulting from 
differential surgical skills and experience. A potential concern is that the pathological 
assessment of removed lymph nodes is dependent on the experience and interest of the 
responsible pathologist, which could introduce exposure misclassification and dilutions of 
associations. A major strength was therefore that only highly specialized and dedicated 
upper gastrointestinal pathologists performed these assessments in all patients included in 
this study. The strong associations between identified metastatic nodes and prognosis 
confirm the validity of the pathological nodal assessment. The outcome mortality was 
completely and accurately assessed for all patients since there were no losses to follow-up in 
this single-center study, where all patients were followed up routinely for at least 5 years 
14 
 
following surgery. Bias from confounding can never be excluded in an observational study, 
but the ability to adjust the results for all known strong prognostic factors counteracts 
confounding. Since we could not enlarge this study and had data from our previous study,11 
we did not perform any sample size calculations. Despite the large sample, chance might be 
a concern since the power to verify weak associations was limited, particularly in the 
stratified analyses. However, the overall results showed no dose-response associations 
between total lymphadenectomy and mortality independent of various categorizations and 
stratifications, and the HRs were generally close to unity, particularly during the more recent 
calendar period. Finally, the multi-ethnic population of London suggests that the results 
might be generalizable.    
 
The lack of any clearly decreased mortality with more extensive lymphadenectomy in this 
study supports the findings of our recent study on this topic.11 That study included 1,044 
patients and from Sweden, and found no decreased mortality following a more extensive 
lymphadenectomy (HR 1.00, 95% CI 0.99-1.01 when number of removed nodes were 
analyzed as a continuous variable).11 These results challenge clinical guidelines 
recommending 2-field lymphadenectomy. The scientific evidence supporting more extensive 
lymphadenectomy (2-field or even 3-field lymphadenectomy) is limited and the topic is 
controversial.5-9 Our findings are contradictory to those of a study using data from a 
consortium of institutions, where a greater extent of lymphadenectomy was followed by 
better survival,17 and in a meta-analysis comparing 2-field or even 3-field lymphadenectomy 
that indicated better 5-year survival rates with 3-field dissection.19 However, these findings 
were derived from studies that might be hampered by stage migration issues, since a more 
extensive lymph node yield tends to result in a more accurate assessment of metastatic 
15 
 
nodes and thus higher tumor stage. Moreover, confounding, e.g. by the known prognostic 
factor of surgeon volume is a threat to these studies,20 since more experienced surgeons 
tend to remove more nodes. In our study, all surgeons had a similarly high annual volume of 
esophagectomies, which offers good control of that potential confounding factor. Our 
results are supported by some well-designed studies that found no survival difference 
between a more extensive lymphadenectomy via transthoracic esophagectomy and a more 
limited lymphadenectomy by a transhiatal approach; a large Dutch randomized clinical 
trial,21,22 our recent cohort study,13 and a meta-analysis of 52 studies.23 Moreover, a 
randomized clinical trial comparing 2-field with 3-field lymphadenectomy found no 
difference in survival.24  
 
Presence of metastatic lymph nodes and a high lymph node ratio strongly predicted survival 
in this study, which confirms the results of previous studies.14 These findings highlight the 
relevance of not only considering the presence or absence of metastatic nodes, but also the 
number of involved nodes in the prediction of prognosis.25 Thus, a limited level of 
lymphadenectomy provides a good basis for prognosis prediction.  
  
The results of this study indicate a need for further research addressing the value of more 
and less extensive lymphadenectomy, e.g. a multi-site interventional study comparing wide 
excision of lymph nodes versus standard excision. Yet, it might be justified to compare the 
results of this study with the developments in lymphadenectomy during surgery for other 
tumors. In breast cancer, the previously advocated more extensive lymphadenectomy did 
not improve survival,26 but increased morbidity.27 As a result, a less extensive and more 
tailored approach to lymphadenectomy has been adopted. A similar development has been 
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seen in the treatment of endometrial cancer.28,29 Among other gastrointestinal cancers, 
recent meta-analyses reveal no evident survival benefits with extended lymphadenectomy 
during surgery for pancreatic, gastric or rectal cancer.30-33 It is possible that 
lymphadenectomy does not improve survival in esophageal cancer simply because positive 
nodes represent a disseminated disease, while non-metastatic nodes do not need to be 
removed.  
 
In conclusion, this cohort study with adjustment for prognostic factors from a dedicated 
esophageal cancer center suggests that the extent of lymphadenectomy does not influence 
survival after surgery for esophageal cancer. These results challenge current guidelines and 
need confirmation in further research. 
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Table 1. Characteristics of 606 patients who underwent esophagectomy for cancer in 2000-
2012. 
 
* This category includes tumors that are well-differentiated, high-grade dysplasia or complete 
pathological response to pre-operative chemotherapy. 
† Circumferential resection margin <1mm from the tumor.  
‡ Grading of response to pre-operative chemotherapy, where scores 1-3 represent good to moderate 
response, 3-4 represent poor or no response and NA represents the group where no pre-operative 
chemotherapy was given. 
 
  
Characteristics  Categorization  Total 
cohort 
Total lymph nodes removed in quartiles [range] 
 
 
 
  I [0-10] II [11-14] III [15-20] IV [21-52] 
 
 
 
 N (%) N (%) N (%) N (%) N (%) 
Total  
 
 606 (100) 166 (27) 139 (23) 151 (25) 150 (25) 
5-year mortality   All-cause  323 (53) 87 (52) 69 (50) 86 (57) 81 (54) 
  Disease-specific  235 (39) 67 (40) 52 (37) 59 (39) 57 (38) 
Age (years)  Median [range]   64 [29-83] 63 [29-80] 64 [38-83] 64 [34-83] 65 [32-81] 
T-stage        T0-T2                     311 (51) 90 (54) 77 (55) 72 (48) 72 (48) 
               T3-T4                     295 (49) 76 (46) 62 (45) 79 (52) 78 (52) 
Tumor differentiation      Well*     71 (12) 26 (16) 18 (13) 13 (9) 14 (9) 
               Moderate                  331 (55) 85 (51) 75 (54) 92 (61) 79 (53) 
               Poor   204 (34) 55 (33) 46 (33) 46 (30) 57 (38) 
Resection      R0                        340 (56) 88 (53) 82 (59) 88 (58) 82 (55) 
               R1 or R2†                266 (44) 78 (47) 57 (41) 63 (42) 68 (45) 
Mandard score‡  1, 2 or 3                 163 (27) 36 (22) 35 (25) 41 (27) 51 (34) 
               4 or 5                   196 (32) 28 (17) 50 (36) 58 (38) 60 (40) 
               NA                        215 (35) 84 (51) 50 (36) 45 (30) 36 (24) 
               Missing   32 (5) 18 (11) 4 (3) 7 (5) 3 (2) 
Calendar period  2000-2006                367 (61) 126 (76) 88 (63) 79 (52) 74 (49) 
               2007-2012                239 (39) 40 (24) 51 (37) 72 (48) 76 (51) 
20 
 
Table 2. All-cause and disease-specific 5-year mortality after esophageal cancer surgery in 
relation to lymph node variables, presented as hazard ratios (HR) with 95% confidence 
intervals (CI). 
 
 
* Adjusted for age, pathological T-stage, tumor differentiation, margin status, response to pre-
operative chemotherapy and calendar period.  
  
Exposure Patients  5-year all-cause mortality  5-year disease-specific mortality 
 
N (%) 
 
 Crude 
HR (95% CI) 
Adjusted* 
HR (95% CI) 
 
Crude 
HR (95% CI) 
Adjusted* 
HR (95% CI) 
Number of 
nodes 
(decentiles) 
  
  
 
  
0-6 76 (13)  1 (reference) 1 (reference)  1 (reference) 1 (reference) 
7-9 64 (11)  1.14 (0.71-1.82) 0.71 (0.44-1.16)  1.10 (0.65-1.87) 0.71 (0.41-1.23) 
10-11 55 (9)  1.28 (0.80-2.05) 0.81 (0.49-1.32)  0.98 (0.56-1.73) 0.66 (0.37-1.19) 
12-13 76 (13)  1.21 (0.77-1.89) 0.85 (0.54-1.35)  1.23 (0.75-2.02) 0.91 (0.55-1.53) 
14-14 34 (6)  0.86 (0.46-1.58) 0.82 (0.44-1.52)  0.76 (0.37-1.55) 0.79 (0.38-1.64) 
15-16 62 (10)  1.43 (0.91-2.25) 1.03 (0.65-1.64)  1.39 (0.84-2.31) 1.06 (0.63-1.79) 
17-19 69 (11)  1.10 (0.70-1.74) 0.66 (0.41-1.06)  0.86 (0.50-1.49) 0.55 (0.31-0.97) 
20-22 49 (8)  1.58 (0.98-2.57) 0.87 (0.52-1.43)  1.18 (0.66-2.11) 0.66 (0.36-1.22) 
23-28 68 (11)  1.09 (0.69-1.73) 0.64 (0.39-1.04)  0.84 (0.49-1.46) 0.53 (0.30-0.95) 
29-52 53 (9)  1.18 (0.72-1.92) 0.72 (0.43-1.20)  1.19 (0.69-2.04) 0.80 (0.45-1.41) 
Number of 
nodes 
(quartiles) 
  
  
 
  
0-10 166 (27)  1 (reference) 1 (reference)  1 (reference) 1 (reference) 
11-14 139 (23)  0.98 (0.72-1.35) 0.93 (0.67-1.30)  0.96 (0.67-1.39) 0.94 (0.65-1.38) 
15-20 151 (25)  1.16 (0.86-1.56) 0.93 (0.68-1.26)  1.03 (0.73-1.47) 0.85 (0.59-1.22) 
21-52 150 (25)  1.07 (0.79-1.44) 0.86 (0.63-1.17)  0.97 (0.68-1.39) 0.83 (0.57-1.20) 
Number of  
metastatic 
nodes  
  
  
 
  
0 274 (45)  1 (reference) 1 (reference)  1 (reference) 1 (reference) 
1-2 136 (22)  2.75 (2.02-3.75) 2.04 (1.49-2.80)  3.34 (2.30-4.85) 2.45 (1.67-3.59) 
3-6 116 (19)  4.90 (3.61-6.64) 2.82 (2.03-3.92)  5.99 (4.15-8.65) 3.32 (2.24-4.94) 
>6 80 (13)  6.58 (4.74-9.14) 3.48 (2.43-4.98)  8.04 (5.42-11.9) 3.84 (2.50-5.91) 
Ratio of 
metastatic to 
all nodes  
  
  
 
  
0 274 (45)  1 (reference) 1 (reference)  1 (reference) 1 (reference) 
0.02-0.14 111 (18)  2.56 (1.84-3.56) 1.84 (1.31-2.59)  3.01 (2.02-4.48) 2.23 (1.48-3.36) 
0.15-0.37 111 (18)  3.98 (2.91-5.44) 2.46 (1.77-3.44)  4.81 (3.30-7.02) 2.79 (1.87-4.18) 
>0.37 110 (18)  7.10 (5.25-9.61) 4.12 (2.95-5.77)  8.97 (6.24-12.9) 4.64 (3.11-6.95) 
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Table 3. T-stage stratified mortality after esophageal cancer surgery in relation to lymph 
node variables, presented as adjusted hazard ratios (HR) with 95% confidence intervals (CI)*. 
 
 
* Adjusted for age, pathological T-stage, tumor differentiation, margin status, response to pre-
operative chemotherapy and calendar period.  
  
Exposure Number of 
patients 
 
5-year all-cause mortality  5-year disease-specific mortality 
 
T-stage  T-stage 
 
T-stage 
T0-T2 T3-T4  T0-T2 T3-T4 T0-T2 T3-T4 
 
N (%) N (%)  HR (95% CI) HR (95% CI)  HR (95% CI) HR (95% CI) 
Number of 
nodes 
(quartiles) 
 
 
  
 
  
0-10   90 (29) 76 (26)  1 (reference) 1 (reference)  1 (reference) 1 (reference) 
11-14   77 (25) 62 (21)  0.59 (0.33-1.04) 1.22 (0.82-1.82)  0.59 (0.29-1.19) 1.18 (0.75-1.85) 
15-20   72 (23) 79 (27)  1.06 (0.64-1.76) 0.87 (0.59-1.28)  1.12 (0.60-2.10) 0.75 (0.48-1.18) 
21-52   72 (23) 78 (26)  0.96 (0.58-1.60) 0.80 (0.54-1.19)  0.92 (0.48-1.76) 0.78 (0.50-1.23) 
Number of  
metastatic 
nodes  
 
 
  
 
  
0 192 (62) 82 (28)  1 (reference) 1 (reference)  1 (reference) 1 (reference) 
1-2   69 (22) 67 (23)  1.69 (1.07-2.68) 2.41 (1.55-3.74)  1.91 (1.07-3.41) 2.95 (1.76-4.96) 
3-6   35 (11) 81 (27)  2.86 (1.70-4.79) 2.97 (1.93-4.55)  3.25 (1.69-6.24) 3.59 (2.16-5.96) 
>6   15 (5) 65 (22)  3.15 (1.61-6.17) 3.77 (2.42-5.86)  3.46 (1.50-7.96) 4.22 (2.50-7.13) 
Ratio of  
metastatic to 
all nodes 
 
 
  
 
  
0 192 (62) 82 (28)  1 (reference) 1 (reference)  1 (reference) 1 (reference) 
0.02-0.14   60 (19) 51 (17)  1.55 (0.95-2.53) 2.15 (1.34-3.45)  2.02 (1.11-3.66) 2.43 (1.38-4.29) 
0.15-0.37   41 (13) 70 (24)  2.84 (1.72-4.68) 2.39 (1.53-3.71)  2.54 (1.30-4.94) 3.02 (1.80-5.07) 
>0.37   18 (6) 92 (31)  3.43 (1.87-6.31) 4.43 (2.92-6.74)  3.94 (1.89-8.21) 5.07 (3.08-8.35) 
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Table 4. Calendar period stratified mortality after esophageal cancer surgery in 2000-2006 
and 2007-2012 in relation to lymph node variables, presented as adjusted hazard ratios (HR) 
with 95% confidence intervals (CI)*. 
 
* Adjusted for age, pathological T-stage, tumor differentiation, margin status, response to pre-
operative chemotherapy and calendar period.   
 
 
 
 
 
 
 
Exposures Number of patients  5-year all-cause mortality  5-year disease-specific mortality 
 Calendar period  Calendar period  Calendar period 
 2000-2006 2007-2012  2000-2006 2007-2012  2000-2006 2007-2012 
 N (%)     N (%)  HR (95% CI) HR (95% CI)  HR (95% CI) HR (95% CI) 
Number of 
nodes 
(quartiles)  
   
 
  
 
  
0-10 126 (34) 40 (17)  1 (reference) 1 (reference)  1 (reference) 1 (reference) 
11-14 88 (24) 51 (21)  0.80 (0.54-1.19) 1.32 (0.74-2.35)  0.87 (0.56-1.35) 1.22 (0.58-2.59) 
15-20 79 (22) 72 (30)  0.88 (0.59-1.29) 1.09 (0.64-1.87)  0.77 (0.49-1.21) 1.07 (0.54-2.13) 
21-52 74 (20) 76 (32)  0.83 (0.56-1.24) 0.98 (0.57-1.66)  0.81 (0.52-1.28) 0.93 (0.47-1.84) 
Number of  
metastatic 
nodes  
   
 
  
 
  
0 173 (47) 101 (42)  1 (reference) 1 (reference)  1 (reference) 1 (reference) 
1-2 89 (24) 47 (20)  2.10 (1.43-3.07) 1.96 (1.12-3.41)  2.56 (1.65-3.99) 2.19 (1.03-4.65) 
3-6 59 (16) 57 (24)  2.48 (1.64-3.75) 3.37 (2.02-5.62)  3.07 (1.92-4.93) 3.83 (1.92-7.66) 
>6 46 (13) 34 (14)  2.76 (1.77-4.30) 5.10 (2.91-8.96)  3.15 (1.90-5.22) 6.00 (2.83-12.7) 
Ratio of  
metastatic 
to all nodes  
   
 
  
 
  
0 173 (47) 101 (42)  1 (reference) 1 (reference)  1 (reference) 1 (reference) 
0.02-0.14 64 (17) 47 (20)  1.97 (1.30-3.00) 1.78 (1.01-3.13)  2.41 (1.49-3.90) 2.03 (0.95-4.37) 
0.15-0.37 59 (16) 52 (22)  1.94 (1.27-2.97) 3.50 (2.07-5.90)  2.46 (1.52-3.97) 3.66 (1.79-7.47) 
>0.37 71 (19) 39 (16)  3.45 (2.32-5.13) 5.85 (3.40-10.1)  3.93 (2.49-6.22) 7.12 (3.47-14.6) 
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Table 5. Mortality following stratification for chemotherapy response in patients undergoing esophageal cancer surgery in relation to lymph 
node variables, presented as adjusted hazard ratios (HR) with 95% confidence intervals (CI)1. 
 
 
1 Adjusted for age, pathological T-stage, tumor grade, margin status, response to pre-operative chemotherapy and calendar period; 2No chemotherapy 
given; 3 Mandard score 1-3; 4 Mandard score 4-5. 
Exposures Number of patients  5-year all-cause mortality  5-year disease-specific mortality 
 Chemotherapy response  Chemotherapy response  Chemotherapy response 
 Not applicable
2
 Good
3
 Poor
4
  Not applicable
2
 Good
3
 Poor
4
  Not applicable
2
 Good
3
 Poor
4
 
 N (%) N (%) N (%)  HR (95% CI) HR (95% CI) HR (95% CI)  HR (95% CI) HR (95% CI) HR (95% CI) 
Number of 
nodes  
     
   
 
 
  
 
0-10 84 (39) 45 (25) 37 (17)  1 (reference) 1 (reference) 1 (reference)  1 (reference) 1 (reference) 1 (reference) 
11-14 50 (23) 37 (21) 52 (24)  1.11 (0.64-1.95) 0.76 (0.37-1.57) 0.89 (0.52-1.50)  1.06 (0.54-2.06) 0.87 (0.41-1.87) 0.92 (0.49-1.71) 
15-20 45 (21) 44 (25) 62 (29)  0.86 (0.48-1.54) 1.13 (0.60-2.14) 0.85 (0.51-1.40)  0.95 (0.49-1.85) 0.65 (0.28-1.50) 0.87 (0.48-1.58) 
21-52 36 (17) 52 (29) 62 (29)  1.03 (0.56-1.90) 0.91 (0.50-1.67) 0.75 (0.45-1.24)  0.97 (0.46-2.06) 0.77 (0.38-1.54) 0.79 (0.44-1.44) 
Number of 
metastatic 
nodes  
     
 
  
 
 
  
 
0 132 (61) 92 (52) 50 (23)  1 (reference) 1 (reference) 1 (reference)  1 (reference) 1 (reference) 1 (reference) 
1-2 34 (16) 49 (28) 53 (25)  1.02 (0.53-1.96) 2.64 (1.52-4.57) 2.48 (1.42-4.33)  1.69 (0.82-3.49) 2.93 (1.51-5.69) 2.59 (1.33-5.04) 
3-6 33 (15) 26 (15) 57 (27)  3.22 (1.90-5.46) 4.30 (2.30-8.06) 2.30 (1.33-3.98)  3.99 (2.07-7.71) 4.87 (2.28-10.4) 2.55 (1.33-4.88) 
>6 16 (7) 11 (6) 53 (25)  2.52 (1.28-4.96) 2.33 (0.96-5.68) 4.16 (2.40-7.20)  3.11 (1.37-7.05) 2.37 (0.80-7.06) 4.19 (2.19-8.04) 
Ratio of  
metastatic to 
all nodes  
     
 
  
 
 
  
 
0 132 (61) 92 (52) 50 (23)  1 (reference) 1 (reference) 1 (reference)  1 (reference) 1 (reference) 1 (reference) 
0.02-0.14 24 (11) 42 (24) 45 (21)  0.89 (0.41-1.93) 2.49 (1.40-4.44) 2.10 (1.17-3.74)  1.57 (0.68-3.63) 2.77 (1.37-5.59) 2.20 (1.10-4.42) 
0.15-0.37 32 (15) 26 (15) 53 (25)  2.41 (1.37-4.24) 4.17 (2.23-7.80) 2.14 (1.23-3.73)  2.96 (1.49-5.91) 4.78 (2.25-10.1) 2.23 (1.16-4.29) 
>0.37 27 (13) 18 (10) 65 (31)  3.44 (1.96-6.04) 2.97 (1.44-6.10) 5.01 (2.92-8.57)  4.26 (2.15-8.44) 3.07 (1.29-7.28) 5.22 (2.76-9.87) 
